Show simple item record

dc.contributor.authorDalton, WB
dc.contributor.authorHelmenstine, E
dc.contributor.authorWalsh, N
dc.contributor.authorGondek, LP
dc.contributor.authorKelkar, DS
dc.contributor.authorRead, A
dc.contributor.authorNatrajan, R
dc.contributor.authorChristenson, ES
dc.contributor.authorRoman, B
dc.contributor.authorDas, S
dc.contributor.authorZhao, L
dc.contributor.authorLeone, RD
dc.contributor.authorShinn, D
dc.contributor.authorGroginski, T
dc.contributor.authorMadugundu, AK
dc.contributor.authorPatil, A
dc.contributor.authorZabransky, DJ
dc.contributor.authorMedford, A
dc.contributor.authorLee, J
dc.contributor.authorCole, AJ
dc.contributor.authorRosen, M
dc.contributor.authorThakar, M
dc.contributor.authorAmbinder, A
dc.contributor.authorDonaldson, J
dc.contributor.authorDeZern, AE
dc.contributor.authorCravero, K
dc.contributor.authorChu, D
dc.contributor.authorMadero-Marroquin, R
dc.contributor.authorPandey, A
dc.contributor.authorHurley, PJ
dc.contributor.authorLauring, J
dc.contributor.authorPark, BH
dc.date.accessioned2020-05-28T11:48:50Z
dc.date.issued2019-08-08
dc.identifier.citationThe Journal of clinical investigation, 2019, 129 (11), pp. 4708 - 4723
dc.identifier.issn0021-9738
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3654
dc.identifier.eissn1558-8238
dc.identifier.doi10.1172/jci125022
dc.description.abstractCancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.
dc.formatElectronic
dc.format.extent4708 - 4723
dc.languageeng
dc.language.isoeng
dc.publisherAMER SOC CLINICAL INVESTIGATION INC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCell Line, Tumor
dc.subjectAnimals
dc.subjectHumans
dc.subjectMice
dc.subjectNeoplasms
dc.subjectSerine
dc.subjectGlycine
dc.subjectNeoplasm Proteins
dc.subjectPhosphoproteins
dc.subjectProteome
dc.subjectXenograft Model Antitumor Assays
dc.subjectEnergy Metabolism
dc.subjectMutation
dc.subjectPhosphoglycerate Dehydrogenase
dc.subjectTranscriptome
dc.subjectCellular Reprogramming
dc.subjectRNA Splicing Factors
dc.titleHotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation.
dc.typeJournal Article
rioxxterms.versionofrecord10.1172/jci125022
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-08-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe Journal of clinical investigation
pubs.issue11
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Functional Genomics
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Functional Genomics
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.publication-statusPublished
pubs.volume129
pubs.embargo.termsNot known
icr.researchteamFunctional Genomics
dc.contributor.icrauthorRead, Abigail
dc.contributor.icrauthorNatrajan, Rachael


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0